These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 11478852

  • 1. Stimulation of mitogenic pathways through kinase-impaired mutants of the epidermal growth factor receptor.
    Ewald JA, Coker KJ, Price JO, Staros JV, Guyer CA.
    Exp Cell Res; 2001 Aug 15; 268(2):262-73. PubMed ID: 11478852
    [Abstract] [Full Text] [Related]

  • 2. Autophosphorylation mutants of the EGF-receptor signal through auxiliary mechanisms involving SH2 domain proteins.
    Li N, Schlessinger J, Margolis B.
    Oncogene; 1994 Dec 15; 9(12):3457-65. PubMed ID: 7970705
    [Abstract] [Full Text] [Related]

  • 3. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
    Zhang T, Ma J, Cao X.
    Biochem J; 2003 Dec 01; 376(Pt 2):457-64. PubMed ID: 14498832
    [Abstract] [Full Text] [Related]

  • 4. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
    Danielsen AJ, Maihle NJ.
    Exp Cell Res; 2002 Apr 15; 275(1):9-16. PubMed ID: 11925101
    [Abstract] [Full Text] [Related]

  • 5. Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor.
    Burgaud JL, Baserga R.
    Exp Cell Res; 1996 Mar 15; 223(2):412-9. PubMed ID: 8601418
    [Abstract] [Full Text] [Related]

  • 6. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.
    Boerner JL, Danielsen AJ, Lovejoy CA, Wang Z, Juneja SC, Faupel-Badger JM, Darce JR, Maihle NJ.
    Oncogene; 2003 Oct 02; 22(43):6679-89. PubMed ID: 14555981
    [Abstract] [Full Text] [Related]

  • 7. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
    Huang L, Watanabe M, Chikamori M, Kido Y, Yamamoto T, Shibuya M, Gotoh N, Tsuchida N.
    Oncogene; 2006 Oct 19; 25(49):6457-66. PubMed ID: 16702953
    [Abstract] [Full Text] [Related]

  • 8. The protein kinase C inhibitor Go6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] potentiates agonist-induced mitogen-activated protein kinase activation through tyrosine phosphorylation of the epidermal growth factor receptor.
    Shah BH, Olivares-Reyes JA, Catt KJ.
    Mol Pharmacol; 2005 Jan 19; 67(1):184-94. PubMed ID: 15465928
    [Abstract] [Full Text] [Related]

  • 9. Identification of epidermal growth factor receptor- Grb2-associated binder-1-SHP-2 complex formation and its functional loss during neoplastic cell progression.
    Kameda H, Risinger JI, Han BB, Baek SJ, Barrett JC, Glasgow WC, Eling TE.
    Cell Growth Differ; 2001 Jun 19; 12(6):307-18. PubMed ID: 11432805
    [Abstract] [Full Text] [Related]

  • 10. EGF receptor-mediated, c-Src-dependent, activation of Stat5b is downregulated in mitogenically responsive hepatocytes.
    Guren TK, Ødegård J, Abrahamsen H, Thoresen GH, Susa M, Andersson Y, Østby E, Christoffersen T.
    J Cell Physiol; 2003 Jul 19; 196(1):113-23. PubMed ID: 12767047
    [Abstract] [Full Text] [Related]

  • 11. Regulation of EGF signaling by cell polarity in MDCK kidney epithelial cells.
    Hobert ME, Friend LA, Carlin CR.
    J Cell Physiol; 1999 Nov 19; 181(2):330-41. PubMed ID: 10497312
    [Abstract] [Full Text] [Related]

  • 12. Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA.
    Li J, Ma C, Huang Y, Luo J, Huang C.
    Oncogene; 2003 Jan 16; 22(2):211-9. PubMed ID: 12527890
    [Abstract] [Full Text] [Related]

  • 13. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
    Azios NG, Romero FJ, Denton MC, Doherty JK, Clinton GM.
    Oncogene; 2001 Aug 23; 20(37):5199-209. PubMed ID: 11526509
    [Abstract] [Full Text] [Related]

  • 14. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y, Li X, Jiang J, Frank SJ.
    Oncogene; 2006 Dec 07; 25(58):7565-76. PubMed ID: 16785991
    [Abstract] [Full Text] [Related]

  • 15. Loss of three major auto phosphorylation sites in the EGF receptor does not block the mitogenic action of EGF.
    Clark S, Cheng DJ, Hsuan JJ, Haley JD, Waterfield MD.
    J Cell Physiol; 1988 Mar 07; 134(3):421-8. PubMed ID: 3258313
    [Abstract] [Full Text] [Related]

  • 16. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.
    Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ.
    Oncogene; 1996 Jul 04; 13(1):85-96. PubMed ID: 8700557
    [Abstract] [Full Text] [Related]

  • 17. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells.
    Lin J, Freeman MR.
    Prostate; 2003 Jan 01; 54(1):1-7. PubMed ID: 12481249
    [Abstract] [Full Text] [Related]

  • 18. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 19. Ras effector pathway activation by epidermal growth factor is inhibited in vivo by exoenzyme S ADP-ribosylation of Ras.
    Henriksson ML, Rosqvist R, Telepnev M, Wolf-Watz H, Hallberg B.
    Biochem J; 2000 Apr 01; 347 Pt 1(Pt 1):217-22. PubMed ID: 10727422
    [Abstract] [Full Text] [Related]

  • 20. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor.
    Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN, Rosenfeld MG.
    Nature; 2000 Apr 01; 328(6133):820-3. PubMed ID: 3498122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.